Brind.

TD Cowen analysts questioned about revenue decline, while Goldman Sachs inquired about business development.

1 report, 0 independent Updated Jun 26

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Who's involved

What this event is mainly about

TD Cowen BioMarin Pharmaceutical Goldman Sachs

Keep exploring

The entities involved

TD Cowen
American investment bank
- Analyst downgraded Ag Growth International Inc. due to debt management risks.Mon 12:33
- TD Cowen raised its price target and gave a buy rating for Travere Therapeutics, Inc., while various institutional investors bought into the company.Mon 10:36
BioMarin Pharmaceutical
American company
- Investors are comparing the financial performance metrics of BioMarin Pharmaceutical and Metagenomi.Sun 20:41
Goldman Sachs
American investment bank
- US-Iran truce aims to reopen Strait of Hormuz amid global monetary policy shifts and oil price drops.Mon 17:37
- Goldman Sachs, Morgan Stanley, JPMorgan Chase, and Bank of America are competing in the global investment banking sector.Mon 17:24

Related events

TD Cowen provided analyst ratings and price targets for Ardelyx, accompanied by required stock transaction filings with the SEC.Aug 26
TD Cowen upgraded Cabaletta Bio shares to strong-buy, while Jefferies reissued a buy rating, and MarketBeat provided consensus data.Sep 14

Coverage

Newest first; wire copies grouped

Jun 26Unknown outlet